Session Type: Poster Session (Sunday)
Session Time: 9:00AM-11:00AM
Background/Purpose: Anti-HMGCR antibodies have been associated with a severe form of immune-mediated necrotizing myopathy (IMNM) with a poor muscle strength recovery and early muscle damage. These patients tend to require aggressive immunosuppressive therapy and present relapsing disease course. Our objective was to evaluate real-life treatment strategies in anti-HMGCR IMNM patients.
Methods: This monocentric study included all patients with anti-HMGCR IMNM with at least 12 months of follow-up. Medical records were retrospectively reviewed to assess clinical features at diagnosis, HLA typing, treatment strategies over the follow-up period (including corticosteroid (CS) use, number of immunosuppressive (IS) agent and intravenous immunoglobulin (IVIg) duration), disease course, and clinical status and therapeutic profile at last follow-up. Remission was defined as the presence of CK level ≤ 2 times the upper limit of normal associated with a stable manual muscle testing for ≥3 months. Quantitative variables are reported as median [IQR1-IQR3].
Results: Thirty-five patients were included. Age at diagnosis was 47.1 [26.1-60.2] years, 74% of patients were female, 29% were statin-exposed, all patients presented with muscle weakness (deltoid and psoas MRC-5 was 4.0 [2-4] and 4.0 [3-4], respectively) and highest CK level was 8146 [5000-12090] IU/L. Time from symptoms onset to treatment initiation was 0.8 [0.3-4.7] years. During the follow-up period, 91% of patients were treated with CS in combination with an IS agent, the majority of patients received IVIg (91%) and the number of treatment intensification was 2 [1-4]. Fourty percent of patients also received plasma exchanges as part of induction therapy.
All patients demonstrated a chronic disease course and no patients were in treatment-free remission at last follow-up after 4.9 [3.1-8.9] years. At last follow-up, 60% of patients were in remission – most of which with IVIg (71%) -, 57% of patients were still receiving CS (CS dose was 8 [5-10] mg/day) and 54% of patients had an IS agent. At last follow-up, only 40% of patients had a normal muscle strength, deltoid and psoas MRC-5 was 5 [4-5] and 4 [3-5], respectively, and CK level was 299 [200-559] IU/L. No predictors of remission or IVIg use at last follow-up were identified, including demographic features, HLA-DRB1*11:01 and HLA-DRB1*07:01 status, muscle disease severity at onset and statin use. Therapy-related side effects were reported in 26% of patients.
Conclusion: In our population, anti-HMGCR IMNM was associated with a chronic disease course associated with IVIg-dependance.
To cite this abstract in AMA style:Landon-Cardinal O, Mariampillai K, Anquetil C, Rigolet A, Hervier B, Champtiaux N, Benveniste O, Allenbach Y. Chronic Disease Course and IVIg-dependance in Long-term Follow-up of Anti-HMGCR Immune-mediated Necrotizing Myopathy [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/chronic-disease-course-and-ivig-dependance-in-long-term-follow-up-of-anti-hmgcr-immune-mediated-necrotizing-myopathy/. Accessed October 27, 2020.
« Back to 2019 ACR/ARP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/chronic-disease-course-and-ivig-dependance-in-long-term-follow-up-of-anti-hmgcr-immune-mediated-necrotizing-myopathy/